Background: According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count ≥ 450 × 109/L, reduced from the previously published WHO 2001 indicated level ≥ 600 × 109/L, was considered the new PLT threshold for the diagnosis of essential thrombocythemia (ET). Patients and Methods: To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT ≥ 600 × 109/L) (124 patients; 76.5%) and Group B (PLT ≥ 450 × 109/L < 600 × 109/L) (38 patients; 23.5%). Results: Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P = .336). The 5-year overall survival (OS) of the entire cohort was 96.9% (95% confidence interval, 92.6%-100%), without differences between the 2 groups (P = .255). Conclusions: Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria.

Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort / Chiatamone Ranieri, S.; Arleo, M. A.; Trasarti, S.; Bizzoni, L.; Carmosino, I.; De Luca, M. L.; Mohamed, S.; Mariggio, E.; Scalzulli, E.; Rosati, S.; De Benedittis, D.; Colafigli, G.; Pepe, S.; Molica, M.; Scamuffa, M. C.; Di Prima, A.; Ferretti, A.; Baldacci, E.; Mancini, M.; Santoro, C.; Vignetti, M.; Breccia, M.; Latagliata, R.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 21:4(2021), pp. e328-e333. [10.1016/j.clml.2020.11.003]

Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort

Chiatamone Ranieri S.;Bizzoni L.;Carmosino I.;Mohamed S.;Scalzulli E.;Colafigli G.;Pepe S.;Molica M.;Scamuffa M. C.;Ferretti A.;Baldacci E.;Santoro C.;Vignetti M.;
2021

Abstract

Background: According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count ≥ 450 × 109/L, reduced from the previously published WHO 2001 indicated level ≥ 600 × 109/L, was considered the new PLT threshold for the diagnosis of essential thrombocythemia (ET). Patients and Methods: To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT ≥ 600 × 109/L) (124 patients; 76.5%) and Group B (PLT ≥ 450 × 109/L < 600 × 109/L) (38 patients; 23.5%). Results: Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P = .336). The 5-year overall survival (OS) of the entire cohort was 96.9% (95% confidence interval, 92.6%-100%), without differences between the 2 groups (P = .255). Conclusions: Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria.
Diagnostic threshold; Platelets; Real-life assessment; Thrombosis; WHO classification; Aged; Cytostatic Agents; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Platelet Count; Prognosis; Reference Values; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombosis; World Health Organization
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort / Chiatamone Ranieri, S.; Arleo, M. A.; Trasarti, S.; Bizzoni, L.; Carmosino, I.; De Luca, M. L.; Mohamed, S.; Mariggio, E.; Scalzulli, E.; Rosati, S.; De Benedittis, D.; Colafigli, G.; Pepe, S.; Molica, M.; Scamuffa, M. C.; Di Prima, A.; Ferretti, A.; Baldacci, E.; Mancini, M.; Santoro, C.; Vignetti, M.; Breccia, M.; Latagliata, R.. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 21:4(2021), pp. e328-e333. [10.1016/j.clml.2020.11.003]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1617966
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact